Skip to main content
Epitomee Medical Ltd. logo

Epitomee Medical Ltd. — Investor Relations & Filings

Ticker · EPIT ISIN · IL0011825911 TA Manufacturing
Filings indexed 14 across all filing types
Latest filing 2026-05-17 Investor Presentation
Country IL Israel
Listing TA EPIT

About Epitomee Medical Ltd.

https://epitomeemedical.com/

Epitomee Medical Ltd. develops and commercializes ingestible therapeutic devices for chronic diseases. The company's core technology is a platform based on a self-administered, swallowable capsule that deploys targeted therapies along the gastrointestinal (GI) tract. These devices are engineered for controlled activation in specific regions, such as the stomach or small intestine, to provide mechano-sensory stimulation, targeted drug delivery, or absorption management. The therapies have a predetermined duration of activity, after which the device dissolves and is passed naturally. The company's flagship product is an FDA-cleared, drug-free weight management capsule. Epitomee is also advancing a platform for the oral delivery of biologic drugs.

Recent filings

Filing Released Lang Actions
Investor Briefing- May 2026
Investor Presentation Classification · 90% confidence The document is a slide deck titled “May 2026 Investor Briefing” containing company overview, market strategy, product pipeline, milestones, management team and go-to-market plans. It is clearly an investor presentation rather than a regulatory filing, earnings release or annual/interim report. Therefore, it best fits the Investor Presentation category.
2026-05-17 English
Investor Briefing- May 2026
Report Publication Announcement Classification · 95% confidence The document is an immediate material event report filed with the Israel Securities Authority and TASE to notify that a company presentation PDF is attached (Company_Presentation_May_2026_isa.pdf). The text does not contain the actual presentation content or substantive data; it merely announces and attaches the presentation. Under the “menu vs. meal” rule, this is an announcement of a report publication rather than the report itself.
2026-05-17 Hebrew (modern)
Investor Presentation
Investor Presentation Classification · 98% confidence The document is a detailed presentation, indicated by the structure, use of slides/figures, and content focusing on technology, market potential, regulatory progress, clinical trial results (RESET trial), and strategic partnerships (Nestle). The presence of Hebrew text ('שיחת משקיעים', 'הניסוי הוכיח...') alongside English, and the date 'November 2023', suggests an investor update or presentation. The content is too comprehensive and detailed to be a simple Earnings Release (ER) or a short Fund Factsheet (FS). It strongly resembles an Investor Presentation (IP) which typically includes clinical data, strategy, and financial highlights, often used in investor calls or roadshows. The inclusion of a section titled 'שיחת משקיעים' (Investor Call) further supports this. It is not a formal regulatory filing like a 10-K or IR, nor is it just an announcement of a report (RPA).
2023-11-30 Hebrew (modern)
Investor Presentation
Share Issue/Capital Change Classification · 99% confidence The document text is highly fragmented and contains significant non-standard characters (likely due to encoding issues or being a partial/scanned document). However, key indicators are present: the company name 'EPITOMEE MEDICAL LTD', a filing date of '30/11/2023', and references to regulatory bodies/websites like 'www.isa.gov.il' (Israel Securities Authority) and 'www.tase.co.il' (Tel Aviv Stock Exchange). The structure, with tables and placeholders, suggests a formal regulatory filing notification. Crucially, the text mentions a file name '����_��������_isa.pdf' and provides a link to download a file, along with a timestamp for when the announcement was made ('���� ������� ����� ��� ������: 30/11/2023 ����: 09:35'). Given the short length (2434 chars) and the explicit mention of a report being available for download rather than containing the full report content itself, this strongly aligns with the definition of a Report Publication Announcement (RPA). It is an announcement about the publication of a report, not the report itself (like 10-K or IR).
2023-11-30 Russian
Presentation- September 2023
Investor Presentation Classification · 99% confidence The document is a detailed presentation dated September 2023, featuring slides with management team information, company highlights, market potential, regulatory progress, clinical trial designs ('RESET' trial), partnership details (Nestle), and strategic focus areas (Weight Management, Biologics Delivery). The structure, use of bullet points, graphics, and forward-looking statements are characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a short announcement of a report (RPA/RNS).
2023-09-12 English
Presentation- September 2023
Regulatory Filings Classification · 95% confidence The document text is heavily garbled (contains many non-standard characters, likely due to encoding issues in the source text provided), but key structural elements suggest it is a formal regulatory filing announcement rather than a full report. It mentions company details (EPITOMEE MEDICAL LTD), regulatory bodies (isa.gov.il, tase.co.il), a filing date (12/09/2023), and includes placeholders for signatures and a link to a PDF file ('����_isa.pdf'). The presence of a specific date and time for publication ('���� ������� ������� ����� ��� ������: 12/09/2023 ����: 08:00') strongly indicates an announcement about a filing being made public. Given the context of regulatory bodies and the short length (2419 chars), this fits the description of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since RPA is more specific for announcing the release of a report, I will prioritize that, although RNS is a strong fallback.
2023-09-12 Russian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.